A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients
PierFranco Conte, Maria Vittoria Dieci, Giancarlo Bisagni, Patrick Schmid, Alberto Zambelli, F. Piacentini, Michelino De Laurentiis, Adolfo Favaretto, Stefano Tamberi, Giulia Bianchi, C. Zamagni, S. Cinieri, D.C. Corsi, Lucia Del Mastro, Annalisa Ferro, Antonio Giulio Gennari, Marta Mion, Antonino Musolino, Lorenzo Nicolè, Paola Del Bianco, Gian Luca De Salvo, V. Guarneri
Topics & Concepts
MedicineTriple-negative breast cancerAvelumabOncologyBreast cancerInternal medicineRandomized controlled trialCancerImmunotherapyPembrolizumabCancer Immunotherapy and BiomarkersBreast Cancer Treatment StudiesHER2/EGFR in Cancer Research